#United States #Princeton #Kenox Pharmaceuticals #Nasal Spray #Strides Pharma

Kenox Enters into Strategic Product Development Partnership with Strides

In an exciting development, Kenox Pharmaceuticals Inc. has entered into a significant strategic partnership with Strides Pharma Science Ltd. This collaboration focuses on the development of nasal spray products targeting various therapeutic indications for the US market. Kenox, a rapidly growing contract development and manufacturing firm specializing in orally inhaled and nasal drug products (OINDPs), is anticipated to enhance Strides' portfolio significantly.

Dr. Sitaram Velaga, the Founder, President, and CEO of Kenox Pharmaceuticals, expressed enthusiasm about this collaboration, highlighting its importance as a milestone for Kenox. He stated, "This strategic partnership with Strides validates our expertise in the OINDP field and allows us to leverage our capabilities to provide essential drugs to global patients at an affordable price. This collaboration will undoubtedly expedite Kenox's growth trajectory."

Strides Pharma, known for its strong position in regulated markets, will work closely with Kenox on various nasal spray formulations and products. Aditya Kumar, Executive Director of Business Development at Strides, noted that this partnership reinforces their focus on nasal spray technologies, an area where they aim to expand further.

"We are pleased to announce this collaboration with Kenox, which brings deep technical knowledge in the OINDP segment," Kumar stated. "This venture continues to build on the progress Strides has made in the nasal spray domain, and we believe that combining Strides' commercial strengths with Kenox's expertise will significantly enhance our capabilities in delivering affordable and high-quality therapies to US patients."

The specific details of the products to be developed remain under wraps at this stage, but the partnership aims to deliver a robust pipeline of products that align with healthcare initiatives focused on affordability and accessibility.

Kenox was established in 2018 and is headquartered in the Greater Princeton area of New Jersey. The company specializes in developing pharmaceutical aerosol products that include soft mist inhalers, dry powder inhalers, nebulizers, and nasal sprays. Their expertise in formulation design, compounding, and compliance with industry standards will be vital in creating innovative solutions in collaboration with Strides.

On the other hand, Strides Pharma, headquartered in Bengaluru, India, has a significant global footprint with manufacturing facilities in various countries, including India, Italy, Kenya, and the United States. The company is focused on producing complex and challenging drug products for over 100 countries, emphasizing their mission to meet healthcare needs across diverse markets.

In summary, the partnership between Kenox and Strides Pharma reflects a commitment to advancing healthcare solutions. By combining their strengths, the two companies aim to bring new nasal spray products to market, strengthening their respective positions in the pharmaceutical industry while ultimately enhancing patient access to critical medications.

This partnership stands to benefit a wide range of patients in the US as both companies work tirelessly to ensure the affordability and quality of their therapeutic offerings. As they progress, more details about specific products and initiatives are expected to emerge, revealing the full extent of this promising collaboration.